Gastroenterology
Volume 138, Issue 7 , Pages 2246-2259 , June 2010

Risk Factors for Idiosyncratic Drug-Induced Liver Injury

  • Naga Chalasani

      Affiliations

    • Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana
    • Clarian/IU Digestive Diseases Center, Indianapolis, Indiana
    • Corresponding Author InformationReprint requests Address requests for reprints to: Naga Chalasani, MD, Indiana University School of Medicine, RG 4100, 1050 Wishard Boulevard, Indianapolis, Indiana 46202. fax: (317) 278-1949
    • ,
  • Einar Björnsson

      Affiliations

    • Department of Internal medicine, Section of Gastroenterology and Hepatology, Landspitali University Hospital, Reykjavik, Iceland

Received 19 February 2010 ,Accepted 8 April 2010.

References 

  1. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 2009;29:337–347
  2. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22:145–155
  3. Garcia Rodriguez LA, Ruigomez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy. 1997;17:721–728
  4. de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58:71–80
  5. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–455
  6. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954
  7. Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. Am J Gastroenterol. 2007;102:558–562
  8. Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol. 2007;102:2437–2443
  9. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481–489
  10. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521
  11. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–1934e1921–1924
  12. Zimmerman H. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed.. Philadelphia: Lippincott: Williams & Wilkins; 1999;
  13. FDA's Guidance for Industry. Drug induced liver injury: premarketing clinical evaluation. July 2009;http://www.fda.gov/ucm/groups/fdagov-public/fdagov-drugs-gen/documents/document/ucm174090.pdfAccessed: August 20, 2009
  14. Papay JI, Clines D, Rafi R, et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol. 2009;54:84–90
  15. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem. 2009;16:3041–3053
  16. Andrade RJ, Robles M, Ulzurrun E, et al. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics. 2009;10:1467–1487
  17. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis. 2009;29:400–411
  18. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse reactions; current progress and challenges. Nat Rev Drug Discov. 2007;6:904–916
  19. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007;47:513–539
  20. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol. 1999;12:387–395
  21. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489–499
  22. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005;128:116–123
  23. Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44:850–856
  24. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and gender. Hepatology. 2009;49:2001–2009
  25. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44:33–60
  26. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol. 2001;15:897–918
  27. Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989;9:297–301
  28. Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol. 2005;61:135–143
  29. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis. 2007;11:477–505
  30. Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2008;50:511–517
  31. De Valle MB, Av Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24:1187–1195
  32. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10:1018–1023
  33. Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother. 2003;37:1055–1062
  34. Otani K, Kaneko S, Tasaki H, et al. Hepatic injury caused by mianserin. BMJ. 1989;299:519
  35. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003–2009
  36. Lammert C, Niklasson A, Bjornsson E, et al. Oral medications with significant hepatic metabolism are at higher risk for hepatic adverse events. Hepatology. 2010;51:615–620
  37. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest. 1988;82:1826–1832
  38. Keefe EB, Reis TC, Berland JE. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Dig Dis Sci. 1982;27:701–704
  39. Herron G, Bourda S. Jaundice secondary to promazine and an analysis of possible cross sensitivities between phenothiazines derivatives. Gastroenterology. 1960;38:87–90
  40. Lewis JH, Zimmermn HJ, Ishak KG, et al. Enflurane hepatotoxicity (A clinicopathologic study of 24 cases). Ann Intern Med. 1983;98:984–992
  41. Andrejak A, Davion T, Gineston JL, et al. Cross hepatotoxicity between non-steroidal anti-inflammatory. BMJ. 1987;295:180–181
  42. Larrey D, Rueff B, Pessayre D, et al. Cross hepatotoxicity between tricyclic antidepressants. Gut. 1986;27:726–727
  43. Remy AJ, Larrey D, Pageaux GP, et al. Cross hepatotoxicity between tricyclic antidepressants and phenothiazines. Eur J Gastroenterol Hepatol. 1995;7:373–376
  44. Lucena MI, Carvajal A, Andrade RJ, et al. Antidepressants-induced hepatotoxicity. Expert Opin Drug Saf. 2003;2:1–14
  45. Miquel M, Soler A, Vaque A, et al. Suspected cross-hepatotoxicity of flutamide and cyproterone acetate. Liver Int. 2007;27:1144–1147
  46. Spelberg B, Rieg G, Bayer A, et al. Lack of cross hepatotoxicity between fluconazole and voriconazole. Clin Infect Dis. 2003;36:1091–1093
  47. Foo H, Gottlieb T. Lack of cross-hepatotoxicity between voriconazole and posaconazole. Clin Infect Dis. 2007;45:803–805
  48. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet. 2000;356:1587–1591
  49. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol. 1995;23(Suppl 1):16–24
  50. Hasler JA. Pharmacogenetics of cytochromes P450. Mol Aspects Med. 1999;20:12–137
  51. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;25:1411–1421
  52. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes (Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation). Drug Metab Dispos. 1993;21:403–409
  53. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin (A meta-analysis). Chest. 1991;99:465–471
  54. Pessayre D, Bentata M, Degott C, et al. Isoniazid-rifampin fulminant hepatitis (A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction). Gastroenterology. 1977;72:284–289
  55. Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology. 1995;21:929–932
  56. Yasui N, Otani K, Kaneko S, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit. 1995;17:333–335
  57. Hull M, Jones R, Bendall M. Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. BMJ. 1994;309:378
  58. Ricaurte B, Guirguis A, Taylor HC, et al. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother. 2006;40:753–757
  59. Lucena MI, Andrade RJ, Vicioso L, et al. Prolonged cholestasis after raloxifene and fenofibrate interaction: a case report. World J Gastroenterol. 2006;12:5244–5246
  60. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology. 1996;46:465–469
  61. Gopaul S, Farrell K, Abbott F. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. Epilepsia. 2003;44:322–328
  62. Siemes H, Nau H, Schultze K, et al. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia. 1993;34:332–346
  63. Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology. 2002;35:876–882
  64. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90:711–716
  65. Malatjalian DA, Ross JB, Williams CN, et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol. 1996;10:369–375
  66. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111–1118
  67. Zachariae H. Have methotrexate-induced liver fibrosis and cirrhosis become rare? (A matter for reappraisal of routine liver biopsies). Dermatology. 2005;211:307–308
  68. Cross FS, Long MW, Banner AS, et al. Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial. Am Rev Respir Dis. 1980;122:349–353
  69. Pande JN, Singh SP, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996;51:132–136
  70. Dossing M, Wilcke JT, Askgaard DS, et al. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis. 1996;77:335–340
  71. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026–2030
  72. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44:1581–1588
  73. Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf. 2002;1:159–172
  74. Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury?. Gastroenterology. 2004;126:1477–1480
  75. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287–1292
  76. Ekstedt M, Franzen LE, Mathiesen UL, et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007;47:135–141
  77. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453–1463
  78. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006;4:902–907quiz 806
  79. Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res. 2007;37:410–415
  80. Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol. 2006;44:791–797
  81. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31:201–206
  82. Lee BH, Koh WJ, Choi MS, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest. 2005;127:1304–1311
  83. Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol. 2002;97:1198–1203
  84. Hwang SJ, Wu JC, Lee CN, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol. 1997;12:87–91
  85. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002;36:263–270
  86. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity (The role of hepatitis C virus and the human immunodeficiency virus). Am J Respir Crit Care Med. 1998;157:1871–1876
  87. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895–2902
  88. Bonfanti P, Landonio S, Ricci E, et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:316–318
  89. Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis. 2004;38(Suppl 2):S104–S108
  90. Kramer JR, Giordano TP, Souchek J, et al. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005;42:309–314
  91. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182–189
  92. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis. 2007;196:670–676
  93. Ito H, Yoshioka K, Ukai K, et al. The fluctuations of viral load and serum alanine aminotransferase levels in chronic hepatitis C. Hepatol Res. 2004;30:11–17
  94. Jain MK, Parekh NK, Hester J, et al. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS. 2006;20:817–822
  95. Ujfalussy I, Koo E, Sesztak M, et al. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis (A comparative study of 270 cases). Z Rheumatol. 2003;62:155–160
  96. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig. 2006;26:55–62
  97. Bachs L, Pares A, Elena M, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 1992;102:2077–2080
  98. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436–439
  99. Cascio A, Scarlata F, Giordano S, et al. Treatment of human brucellosis with rifampin plus minocycline. J Chemother. 2003;15:248–252
  100. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol. 2008;21:84–92
  101. Donaldson PT, Bhatnagar P, Graham J, et al. Susceptibility to drug induced liver injury determined by HLA class II genotype (abstr). Hepatology. 2008;48(S1):464A
  102. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816–821
  103. Day CP, Stewart JD, Horvath R, et al. Common POLG genetic variants increase the risk of sodium valproate induced liver injury and failure. Hepatology. 2009;50:383A
  104. Scordo MG, Aklillu E, Yasar U, et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black American population. Br J Clin Pharmacol. 2001;52:447–450
  105. Morin S, Loriot MA, Poirier JM, et al. Is diclogenac a valuable CYP2C9 probe in humans?. Eu J Clin Pharmacol. 2001;56:793–797
  106. Aithal GP, Day CP, Leathart JB, et al. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics. 2000;10:511–518
  107. Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol. 2001;57:729–735
  108. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1–16
  109. Horsmans Y, Lannes D, Pessayre D, et al. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate, and difebarbamate. J Hepatol. 1994;21:1075–1079
  110. Kumashiro R, Kuboto T, Koga Y, et al. Association of troglitazone-induced liver injury with mutation of the cytochrome P4502C19 gene. Hepatol Res. 2003;26:337–342
  111. Pachkoria K, Lucena MI, Ruiz-Cabello F, et al. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol. 2007;150:808–815
  112. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003;37:924–930
  113. Vuilleumier N, Rossier MF, Chiape A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol. 2006;62:423–429
  114. Sun F, Chen Y, Xiang Y, et al. Drug-metabolizing enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2008;12:994–1002
  115. Rieder MJ, Shear NH, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther. 1991;49:13–17
  116. Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther. 1975;18:70–79
  117. Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology. 1986;6:295–298
  118. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35:883–889
  119. Shimizu Y, Dobashi K, Mita Y, et al. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinb). 2006;86:374–381
  120. Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2007;3:1–8
  121. Lucena MI, Andrade RJ, Martinez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology. 2008;48:588–596
  122. Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol. 2007;47:128–134
  123. Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132:272–281
  124. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol. 2003;192:307–322
  125. Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004;39:1430–1440
  126. Aithal GP, Day CP, Leathart JB, et al. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics. 2000;10:511–518
  127. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78:260–277
  128. Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology. 2006;44:778–787
  129. Pauli-Magnus C, Stieger B, Meier Y, et al. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol. 2005;43:342–357
  130. Vavricka SR, Van Montfoort J, Ha HR, et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36:164–172
  131. Bolder U, Trang NV, Hagey LR, et al. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology. 1999;117:962–971
  132. Lakehal F, Dansette PM, Becquemont L, et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol. 2001;14:694–701
  133. Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem Res Toxicol. 2001;14:175–181
  134. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69:223–231
  135. Leslie EM, Watkins PB, Kim RB, et al. Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 2007;321:1170–1178
  136. Meier Y, Pauli-Magnus C, Zanger UM, et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology. 2006;44:62–74
  137. Strautnieks SS, Bull LN, Knisely AS, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998;20:233–238
  138. Pauli-Magnus C, Lang T, Meier Y, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics. 2004;14:91–102
  139. Leevy CB, Koneru B, Klein KM. Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease. Gastroenterology. 1997;113:966–972
  140. Meier Y, Zodan T, Lang C, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol. 2008;14:38–45
  141. Noe J, Kullak-Ublick GA, Jochum W, et al. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J Hepatol. 2005;43:536–543
  142. Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007;17:47–60
  143. Ibanez L, Perez E, Vidal X, et al. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol. 2002;37:592–600
  144. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8:186–195
  145. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmcol Ther. 2007;25:1411–1421
  146. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2:301–305
  147. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732
  148. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48:1015–1018
  149. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate–induced hepatitis. Gastroenterology. 1999;117:1181–1186
  150. Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166:916–919
  151. Donaldson PT. Flucloxacillin-induced liver injury, the extended MHC 57.1 haplotype as a major risk factor. Hepatology. 2008;48:396A–397A
  152. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579
  153. O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47:717–720
  154. Andrade RJ, Lucena MI, Alonso A, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology. 2004;39:1603–1612
  155. Berson A, Freneaux E, Larrey D, et al. Possible role of HLA in hepatotoxicity (An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis). J Hepatol. 1994;20:336–342
  156. Pachkoria K, Lucena MI, Crespo E, et al. Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol. 2008;49:107–114

 Conflicts of interest Dr Chalasani has served as a paid consultant within the preceding 12 months to Teva, Eli Lilly, Karobio, Salix, Debiovision, Amylin, Genentech, Abbott, and Gilead on issues related to drug safety, and has research support from Eli Lilly and Monarch LifeSciences; and Dr Björnsson has served as a paid consultant for Astellas Pharma Europe, AstraZeneca, and Karobio.

PII: S0016-5085(10)00542-1

doi: 10.1053/j.gastro.2010.04.001

Gastroenterology
Volume 138, Issue 7 , Pages 2246-2259 , June 2010

Article Tools